FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
ReutersMar 28, 2025 4:43 PM
March 28 (Reuters) - FDA:
FDA EXPANDS PLUVICTO’S METASTATIC CASTRATION-RESISTANT PROSTATE CANCER INDICATION
FDA: EXPANDS PLUVICTO INDICATION TO ADD ADULTS WITH PSMA-POSITIVE MCRPC TREATED WITH ARPI & CONSIDERED APPROPRIATE TO DELAY TAXANE-BASED CHEMO
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.TradingKey
3 hours ago
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.TradingKey
15 hours ago
Eurozone Inflation Gradually Recedes Will ECB Rate-Cut Window Open Again? 2026 Euro Exchange Rate Trend Forecast
TradingKey - After enduring three consecutive years of "high prices, high interest rates, high debt, and low growth," the Eurozone economy is finally demonstrating resilience through a moderate recovery. Currently, the European Central Bank (ECB) faces the ultimate test of maintaining the status quo versus implementing "preemptive rate cuts." Euro exchange rate volatility, inflation trends, and the economic outlook have become the primary focus for investors and financial enthusiasts when allocating overseas assets and capitalizing on currency opportunities.TradingKey
19 hours ago
